26.97
price down icon2.67%   -0.74
after-market Dopo l'orario di chiusura: 26.97
loading
Precedente Chiudi:
$27.71
Aprire:
$27.44
Volume 24 ore:
2.48M
Relative Volume:
1.30
Capitalizzazione di mercato:
$4.45B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
13.83
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
-9.92%
1M Prestazione:
-1.68%
6M Prestazione:
-19.28%
1 anno Prestazione:
+1.54%
Intervallo 1D:
Value
$26.93
$27.68
Intervallo di 1 settimana:
Value
$25.16
$28.65
Portata 52W:
Value
$25.16
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Nome
Alkermes Plc
Name
Telefono
00-353-1-772-8000
Name
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Name
Dipendente
1,800
Name
Cinguettio
@alkermes
Name
Prossima data di guadagno
2024-10-24
Name
Ultimi documenti SEC
Name
ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
26.97 4.45B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
148.20 66.22B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.10 48.29B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.81 43.99B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
19.93 22.45B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
405.02 17.93B 2.99B 1.21B 1.13B 25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-03 Iniziato Wells Fargo Overweight
2025-07-15 Iniziato Goldman Buy
2025-06-17 Aggiornamento UBS Neutral → Buy
2025-05-28 Iniziato Needham Buy
2025-03-13 Iniziato RBC Capital Mkts Sector Perform
2025-03-04 Aggiornamento UBS Sell → Neutral
2025-02-11 Iniziato Deutsche Bank Buy
2024-11-05 Aggiornamento Stifel Hold → Buy
2024-06-17 Iniziato TD Cowen Buy
2024-03-19 Iniziato Robert W. Baird Outperform
2024-02-20 Downgrade UBS Neutral → Sell
2023-11-20 Ripresa JP Morgan Neutral
2023-10-24 Aggiornamento Evercore ISI In-line → Outperform
2023-10-17 Iniziato UBS Neutral
2022-11-03 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-14 Aggiornamento BofA Securities Underperform → Neutral
2022-08-16 Iniziato Piper Sandler Neutral
2022-04-22 Ripresa Goldman Buy
2022-04-20 Iniziato Goldman Buy
2022-01-27 Aggiornamento Cantor Fitzgerald Hold → Overweight
2021-12-01 Iniziato Citigroup Neutral
2021-10-07 Aggiornamento Jefferies Hold → Buy
2021-09-02 Downgrade BofA Securities Neutral → Underperform
2020-10-15 Aggiornamento Mizuho Neutral → Buy
2020-07-30 Downgrade Goldman Neutral → Sell
2020-02-14 Downgrade BofA/Merrill Buy → Neutral
2020-02-14 Reiterato H.C. Wainwright Neutral
2020-02-14 Downgrade JP Morgan Overweight → Neutral
2020-02-06 Iniziato Mizuho Neutral
2020-01-31 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-09-05 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2019-07-15 Aggiornamento Goldman Sell → Neutral
2019-05-31 Iniziato H.C. Wainwright Neutral
2019-05-01 Downgrade Citigroup Buy → Neutral
2018-12-19 Downgrade Goldman Neutral → Sell
2018-12-14 Iniziato Wolfe Research Underperform
2018-12-13 Downgrade Credit Suisse Outperform → Underperform
2018-11-05 Iniziato Piper Jaffray Neutral
2018-08-07 Iniziato Stifel Hold
2018-06-21 Downgrade Morgan Stanley Equal-Weight → Underweight
2018-06-06 Iniziato B. Riley FBR, Inc. Buy
2018-05-16 Aggiornamento Citigroup Neutral → Buy
2018-05-11 Iniziato BofA/Merrill Buy
Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

pulisher
Sep 14, 2025

Alkermes plc $ALKS Shares Sold by AQR Capital Management LLC - MarketBeat

Sep 14, 2025
pulisher
Sep 14, 2025

Amundi Cuts Holdings in Alkermes plc $ALKS - MarketBeat

Sep 14, 2025
pulisher
Sep 14, 2025

Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 14, 2025
pulisher
Sep 14, 2025

Alkermes (NASDAQ:ALKS) Reaches New 1-Year LowHere's Why - MarketBeat

Sep 14, 2025
pulisher
Sep 13, 2025

Alkermes (NASDAQ:ALKS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Sep 13, 2025
pulisher
Sep 13, 2025

Acadian Asset Management LLC Has $29.10 Million Position in Alkermes plc $ALKS - MarketBeat

Sep 13, 2025
pulisher
Sep 13, 2025

Baird Financial Group Inc. Purchases New Shares in Alkermes plc $ALKS - MarketBeat

Sep 13, 2025
pulisher
Sep 13, 2025

Alkermes appoints Joshua Reed as new CFO effective Monday By Investing.com - Investing.com Australia

Sep 13, 2025
pulisher
Sep 12, 2025

Alkermes appoints Joshua Reed as new CFO effective Monday - Investing.com India

Sep 12, 2025
pulisher
Sep 12, 2025

Investors Purchase Large Volume of Alkermes Call Options (NASDAQ:ALKS) - MarketBeat

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes appoints new CFO - MSN

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of VivitrolSEC filing - MarketScreener

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes Appoints Joshua Reed as New CFO - TipRanks

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025 - MarketScreener

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes Appoints Joshua Reed as Chief Financial Officer - Sharecast.com

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes (ALKS) Appoints Joshua Reed as New CFO - GuruFocus

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes appoints Joshua Reed as chief financial officer - MarketScreener

Sep 12, 2025
pulisher
Sep 12, 2025

30-Year Biotech Finance Veteran Joshua Reed Joins Alkermes as CFO After Bristol Myers Leadership - Stock Titan

Sep 12, 2025
pulisher
Sep 12, 2025

While Shareholders of Alkermes (NASDAQ:ALKS) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛

Sep 12, 2025
pulisher
Sep 12, 2025

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - Eastern Progress

Sep 12, 2025
pulisher
Sep 12, 2025

Fred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKS - MarketBeat

Sep 12, 2025
pulisher
Sep 11, 2025

Alkermes' (ALKS) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Sep 11, 2025
pulisher
Sep 10, 2025

Potential Impact on Alkermes (ALKS) from RFK Jr.'s Possible Depa - GuruFocus

Sep 10, 2025
pulisher
Sep 10, 2025

How RFK Jr.'s Potential Exit Could Benefit Alkermes (ALKS) - GuruFocus

Sep 10, 2025
pulisher
Sep 09, 2025

JP Morgan Maintains Neutral Rating for ALKS and Raises Price Tar - GuruFocus

Sep 09, 2025
pulisher
Sep 09, 2025

December 2026 Options Now Available For Alkermes (ALKS) - Nasdaq

Sep 09, 2025
pulisher
Sep 09, 2025

Can Alkermes plc stock outperform in a bear market2025 Risk Factors & Stepwise Trade Signal Guides - Lancaster City Council

Sep 09, 2025
pulisher
Sep 09, 2025

HC Wainwright & Co. Reiterates Neutral Rating for ALKS | ALKS St - GuruFocus

Sep 09, 2025
pulisher
Sep 09, 2025

Alkermes Announces Positive Phase 2 Study Results - MSN

Sep 09, 2025
pulisher
Sep 09, 2025

Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

Alkermes plc $ALKS Shares Acquired by Canada Pension Plan Investment Board - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

Is Alkermes plc stock showing strong momentumJuly 2025 Spike Watch & Reliable Breakout Forecasts - 뉴스영

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes stock hits 52-week low at 25.31 USD By Investing.com - Investing.com Canada

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes (ALKS) Reports Promising Results from Phase 2 Narcoleps - GuruFocus

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com Canada

Sep 08, 2025
pulisher
Sep 08, 2025

Takeda and Alkermes share OX2R drug data for narcolepsy - Yahoo Finance

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes stock hits 52-week low at 25.31 USD - Investing.com

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes (ALKS) Shows Progress in Narcolepsy Study, Faces Invest - GuruFocus

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes : ALKS World Sleep 2025 Prepared Remarks 9 8 2025 FINAL - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Transcript : Alkermes plcShareholder/Analyst Call - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes stock maintains Buy rating at Stifel following sleep disorder data - Investing.com Nigeria

Sep 08, 2025
pulisher
Sep 08, 2025

Real Time Data Flags Unusual Activity in Alkermes plc2025 Investor Takeaways & Daily Oversold Bounce Ideas - beatles.ru

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes plc $ALKS Position Trimmed by Palo Alto Investors LP - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes (ALKS) Reports Promising Phase 2 Results for Narcolepsy Treatment Alixorexton - GuruFocus

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes presents detailed positive results from Vibrance-1 Phase 2 Study of Alixorextin in patients with narcolepsy type 1 - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes Presents Detailed Positive Results From Vibrance-1 Phase 2 Study of Alixorexton in Patients With Narcolepsy Type 1 at World Sleep Congress 2025 - 富途牛牛

Sep 08, 2025
pulisher
Sep 08, 2025

Alkermes (NASDAQ:ALKS) Trading 7.2% Higher Following Analyst Upgrade - MarketBeat

Sep 08, 2025
pulisher
Sep 07, 2025

337,603 Shares in Alkermes plc $ALKS Acquired by MPM Bioimpact LLC - MarketBeat

Sep 07, 2025
pulisher
Sep 06, 2025

Alkermes plc $ALKS Stock Position Reduced by Vident Advisory LLC - MarketBeat

Sep 06, 2025

Alkermes Plc Azioni (ALKS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.53
price down icon 1.33%
$9.96
price down icon 2.06%
drug_manufacturers_specialty_generic RDY
$14.66
price down icon 0.48%
$141.87
price down icon 1.20%
$405.02
price up icon 0.04%
Capitalizzazione:     |  Volume (24 ore):